B-cell receptor pathway modulators in NHL.
B-cell receptor pathway modulators in NHL.
复制标题
DOI：
10.1182/asheducation-2015.1.82
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Blum KA
中科院分区：
文献类型：
--
作者：
Blum KA
随着最近布鲁顿酪氨酸激酶（BTK）抑制剂伊曲替尼和磷酸肌醇-3-激酶（PI 3 K）抑制剂艾代拉里斯在治疗复发性或难治性非霍奇金淋巴瘤（NHL）患者中的成功，许多靶向B细胞受体（BCR）途径的新药正在临床开发中。此外，将这些药物与常规细胞毒性化疗、免疫调节剂、单克隆抗体或其他激酶抑制剂联合使用的多项试验正在进行中。本综述将总结目前的数据与使用单药和联合治疗与BCR抑制剂在NHL。此外，还将讨论常见的严重毒性和假设的耐药机制。最后，本次审查将研究这些药物的未来和机会，以操纵他们进入一线设置在选定的NHL亚型。
With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor, idelalisib, in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), a number of new agents targeting the B-cell receptor (BCR) pathway are in clinical development. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. This review will summarize the current data with the use of single agent and combination therapy with BCR inhibitors in NHL. In addition, commonly encountered as well as serious toxicities and hypothesized resistance mechanisms will be discussed. Lastly, this review will examine the future of these agents and opportunities to maneuver them into the front-line setting in selected NHL subtypes.